Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Onyx Pharmaceuticals

Evaluate

September 27, 2016

Amgen’s Kyprolis Clarion call falls on deaf ears

March 09, 2015

Mealy mouthed data disclosure erases some CTI losses

Vantage logo
March 03, 2015

Amgen still in play with Endeavor to expand Kyprolis

Vantage logo
February 27, 2015

Upcoming events: pacritinib in myelofibrosis and an adcom for Kythera

Vantage logo
February 04, 2015

Palbo puts cyclin back on the agenda

Vantage logo
October 22, 2014

The heat on Amgen is not about to let up

Vantage logo
August 15, 2014

Amgen investors focus beyond Kyprolis trial data

Vantage logo
April 07, 2014

Palbo bull case dissipates as Paloma fires blanks

Vantage logo
February 28, 2014

Bankers pitching biotech acquisitions to Bayer must fight hard

Vantage logo
February 04, 2014

Despite the upgrades, palbo fails to wow Amgen investors

Vantage logo
November 22, 2013

Amgen declares all is well as Kyprolis worries trigger fall

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up